- Home
- DALN vs CMMB Comparison
DALN vs CMMB Comparison
Compare DALN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- CMMB
- Stock Information
- Founded
- DALN 1954
- CMMB 2004
- Country
- DALN United States
- CMMB Israel
- Employees
- DALN N/A
- CMMB N/A
- Industry
- DALN Newspapers/Magazines
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- CMMB Health Care
- Exchange
- DALN Nasdaq
- CMMB Nasdaq
- Market Cap
- DALN 29.3M
- CMMB 27.0M
- IPO Year
- DALN 2008
- CMMB N/A
- Fundamental
- Price
- DALN $5.65
- CMMB $1.61
- Analyst Decision
- DALN
- CMMB Strong Buy
- Analyst Count
- DALN 0
- CMMB 3
- Target Price
- DALN N/A
- CMMB $7.33
- AVG Volume (30 Days)
- DALN 101.6K
- CMMB 119.1K
- Earning Date
- DALN 11-12-2024
- CMMB 11-14-2024
- Dividend Yield
- DALN 11.32%
- CMMB N/A
- EPS Growth
- DALN N/A
- CMMB N/A
- EPS
- DALN N/A
- CMMB N/A
- Revenue
- DALN $128,286,000.00
- CMMB N/A
- Revenue This Year
- DALN N/A
- CMMB N/A
- Revenue Next Year
- DALN N/A
- CMMB N/A
- P/E Ratio
- DALN N/A
- CMMB N/A
- Revenue Growth
- DALN N/A
- CMMB N/A
- 52 Week Low
- DALN $2.98
- CMMB $0.42
- 52 Week High
- DALN $6.47
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- DALN 54.61
- CMMB 53.15
- Support Level
- DALN $4.95
- CMMB $1.55
- Resistance Level
- DALN $6.23
- CMMB $1.73
- Average True Range (ATR)
- DALN 0.54
- CMMB 0.15
- MACD
- DALN -0.01
- CMMB 0.00
- Stochastic Oscillator
- DALN 38.81
- CMMB 45.28
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.